Faget Quoted in MedTech Dive on the FDA’s Response to the COVID Crisis
March 15, 2021
MedTech Dive
Kyle Faget, partner and member of the firm’s Health Care and Life Sciences Industry Team, was quoted in a MedTech Dive article titled, “5 Things Medtech Can Expect from FDA in 2021.”
Faget told MedTech Dive that she sees the FDA in 2021 releasing its long-awaited publication of the revised Quality System Regulation. She also stated that: “What we saw a lot of in the Trump administration was HHS getting very involved in FDA’s business and we’re going to see less of that.” She continued, “There’s going to be much more deference to FDA as an independent regulatory body.”
People
Related News
August 19, 2025
In the News
Gustavo Resendiz Featured in Q&A on Secondary Market Momentum – 'Investors want liquidity'
Foley & Lardner LLP partner Gustavo Resendiz is featured in the Crunchbase News Q&A, "Why Secondary Funds Still Can’t Keep Up With Investor Demand," lending insight into the accelerating investor momentum towards secondary transactions.
August 18, 2025
In the News
David Simon Coauthors Piece on Empowering Lawyers as Strategic Business Partners
Foley & Lardner LLP partner David Simon coauthored The Agenda article, "Turn Your Corporate Lawyer into a Strategic Weapon," published by Financial Times.
August 15, 2025
In the News
Gregory Husisian on Voluntary Disclosures to Customs – 'Importing has never been riskier'
Foley & Lardner LLP partner Gregory Husisian authored the SupplyChainBrain article, "Best Practices for Making Voluntary Disclosures to Customs," sharing insight on this vital strategy for companies looking to mitigate risk from U.S. Customs and Border Protection.